## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -6.6% below STRENGTH zone (4.0-10.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($116.21)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives**
- Source: Finviz | 20251207T015325 | Bullish | Relevance: 100%
- The University of Wisconsin won the Abbott and Big Ten Conference's "We Give Blood" competition, inspiring over 15,000 blood donations and securing $1 million for student or community health. The campaign saw a 319% increase in overall donations and a 168% jump in student donors compared to the previous year, helping to provide nearly 250,000 potential life-saving donations. This initiative highlights the critical need for blood donations, especially from younger demographics, and demonstrates the power of collegiate rivalries for social good.

**2. Ossiam Has $8.77 Million Position in Abbott Laboratories $ABT**
- Source: MarketBeat | 20251209T122959 | Somewhat-Bullish | Relevance: 99%
-  Ossiam reduced its stake in Abbott Laboratories (NYSE:ABT) by 12.2% in the second quarter, now holding 64,496 shares valued at $8.77 million. Despite this, other institutional investors like Vanguard Group Inc. and Geode Capital Management LLC increased their positions in the healthcare product maker. Abbott Laboratories reported meeting analyst earnings expectations for the last quarter and announced a quarterly dividend, while several analysts maintain "buy" or "overweight" ratings with price targets up to $150.00.

**3. Abbott's Lingo CGM Expands to Android, Broadens Glucose Access | ABT Stock News**
- Source: Stock Titan | 20251208T140804 | Somewhat-Bullish | Relevance: 99%
-  Abbott (NYSE: ABT) has made its Lingo continuous glucose monitor and app available on Android, expanding its reach beyond iOS in the U.S. and U.K. This move gives more individuals access to real-time glucose data, enabling informed health choices. New real-world data from Lingo users indicates that protein supplementation is linked to a 15% lower odds of glucose spikes and a 2 mg/dL average glucose reduction, with an even greater benefit for individuals with obesity.

**4. Abbott (ABT) Expands Lingo Glucose Monitor to Android Users**
- Source: GuruFocus | 20251208T144104 | Bullish | Relevance: 98%
-  Abbott (ABT) has expanded the availability of its Lingo continuous glucose monitoring system to Android users, previously only available on Apple iOS. This move broadens the market reach for the device, which helps individuals track real-time glucose levels to improve overall health. Abbott Laboratories, a diversified healthcare company with a $217.5 billion market cap, demonstrates strong financial health despite some insider selling activity.

**5. Institutional shareholders may be less affected by Abbott Laboratories' (NYSE:ABT) pullback last week after a year of 8.3% returns**
- Source: Yahoo Finance | 20251209T110736 | Neutral | Relevance: 98%
-  Institutional investors own 81% of Abbott Laboratories (NYSE:ABT), making the stock's performance sensitive to their trading actions. Despite a 4.6% drop last week, these shareholders have seen an 8.3% return over the past year, which may have softened the impact. The top 25 shareholders collectively hold less than half of the company, with The Vanguard Group, BlackRock, Inc., and Capital Research and Management Company being the largest individual institutional holders.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | BTIG | $145 | $145 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($0.12M) |
| Sells | 1 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.1% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 4.2x requires aggressive growth execution.
3. Long-term trend broken: trading 7.3% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 21.4x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $211.0B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 21.4 |
| Current P/E | 23.5 |
| YoY Growth | 10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -3.5% to -6.6% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.6pp (needs >4.0% for momentum thesis). AM_20 at -4.5% indicates price below own 20MA trend. Below SMA200 (0.93x), long-term trend not supportive. MACD histogram bearish (-0.58), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.60% (CS: 8) | Weak |
| RSI_14 | 33.1 | Neutral |
| MACD Histogram | -0.58 | Bearish |
| vs SMA20 | 0.955x | Below |
| vs SMA50 | 0.946x | Below |
| vs SMA200 | 0.927x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $121.25
- **Stop Loss:** $116.21 (4.2% risk)
- **Target:** $126.29 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 59
- **Position Value:** $7,153.75
- **Portfolio %:** 7.15%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*